Home > Insider Trading > Filing (0000899243-20-032813)

Filing Details

Accession Number:: 0000899243-20-032813
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-04 21:28:09
Reporting Period:: 2020-11-23

Accepted Time:: 2020-12-04 21:28:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1824893	Consonance-Hfw Acquisition Corp.	CHFW	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1097955	Md J Mitchell Blutt	1370 Avenue Of The Americas Suite 3301 New York NY 10019	Yes	No	Yes	No
1544773	Consonance Capital Management Lp	1370 Avenue Of The Americas Suite 3301 New York NY 10019	Yes	No	Yes	No
1620428	Consonance Capman Gp, Llc	1370 Avenue Of The Americas Suite 3301 New York NY 10019	Yes	No	Yes	No
1834998	Consonance Capital Opportunity Fund Management Lp	1370 Avenue Of The Americas Suite 3301 New York NY 10019	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Ordinary Shares	Acquisiton	2020-11-23	500,000	$0.00	500,000	No	4	P	Indirect	By Consonance Capital Master Account, LP
Class A Ordinary Shares	Acquisiton	2020-11-23	371,100	$0.00	371,100	No	4	P	Indirect	By Consonance Capital Opportunity Master Fund, LP
Class A Ordinary Shares	Acquisiton	2020-11-23	128,900	$0.00	128,900	No	4	P	Indirect	By Managed Account

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Consonance Capital Master Account, LP
No	4	P	Indirect	By Consonance Capital Opportunity Master Fund, LP
No	4	P	Indirect	By Managed Account

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Ordinary Shares	434,000	Indirect	By Consonance Life Sciences, LLC

Footnotes

Represents part of units of Consonance-HFW Acquisition Corp. (the "Issuer") purchased in the Issuer's initial public offering for $10 per unit. Each unit consists of one Class A ordinary share ("Class A Share") of the Issuer and one-third of one warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants are not being reported on this Form 4 because they cannot be exercised until the satisfaction of material conditions outside the control of the Reporting Persons.
Consonance Capital Management LP ("Consonance Management") is an indirect beneficial owner of the Class A Shares held by Consonance Capital Master Account, LP (the "Master Account"). Consonance Management is the investment adviser of the Master Account, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by the Master Account. Consonance Capman GP LLC ("Capman") is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the shares held by the Master Account as the manager and member of the general partner of the Master Account and thereby is entitled to a portion of the profits allocation.
(Continued from footnote 2) Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.
Consonance Management is an indirect beneficial owner of the Class A Shares held by Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"). Consonance Management is the investment adviser of Consonance Opportunity Master, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Consonance Opportunity Master. Capman is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the shares held by Consonance Opportunity Master as the manager and member of the general partner of Consonance Opportunity Master and thereby is entitled to a portion of the profits allocation.
(Continued from footnote 4) Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.
Consonance Capital Opportunity Fund Management LP ("Consonance Opportunity") is an indirect beneficial owner of the Class A Shares held by a certain managed account (the "Managed Account"). Consonance Opportunity is the investment adviser of the Managed Account and exercises voting and investment power over the securities of the Issuer held by the Managed Account. Capman is the general partner of Consonance Opportunity. Consonance Opportunity receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.
Consonance Life Sciences, LLC ("Consonance Life Sciences") is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein. The Master Fund, Consonance Opportunity Master and the Managed Account in the aggregate own the majority of the unit interests in Consonance Life Sciences.